Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

Overview of attention for article published in Breast Cancer Research and Treatment, October 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

policy: 2 policy sources

twitter: 2 X users

Citations

dimensions_citation: 70 Dimensions

Readers on

mendeley: 145 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Kisqali for Metastatic Breast Cancer – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 31 Jul 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 03 Apr 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.